Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats....
Ausführliche Beschreibung
Autor*in: |
Nobuaki Egashira [verfasserIn] Yu Goto [verfasserIn] Ryota Takahashi [verfasserIn] Hikari Iba [verfasserIn] Shota Yamamoto [verfasserIn] Takuya Watanabe [verfasserIn] Kaori Kubota [verfasserIn] Takehiro Kawashiri [verfasserIn] Chise Taniguchi [verfasserIn] Shutaro Katsurabayashi [verfasserIn] Katsunori Iwasaki [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Journal of Pharmacological Sciences - Elsevier, 2017, 147(2021), 1, Seite 114-117 |
---|---|
Übergeordnetes Werk: |
volume:147 ; year:2021 ; number:1 ; pages:114-117 |
Links: |
---|
DOI / URN: |
10.1016/j.jphs.2021.06.004 |
---|
Katalog-ID: |
DOAJ006181082 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ006181082 | ||
003 | DE-627 | ||
005 | 20230309195918.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jphs.2021.06.004 |2 doi | |
035 | |a (DE-627)DOAJ006181082 | ||
035 | |a (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
100 | 0 | |a Nobuaki Egashira |e verfasserin |4 aut | |
245 | 1 | 0 | |a Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. | ||
650 | 4 | |a Ibudilast | |
650 | 4 | |a Oxaliplatin | |
650 | 4 | |a Peripheral neuropathy | |
653 | 0 | |a Therapeutics. Pharmacology | |
700 | 0 | |a Yu Goto |e verfasserin |4 aut | |
700 | 0 | |a Ryota Takahashi |e verfasserin |4 aut | |
700 | 0 | |a Hikari Iba |e verfasserin |4 aut | |
700 | 0 | |a Shota Yamamoto |e verfasserin |4 aut | |
700 | 0 | |a Takuya Watanabe |e verfasserin |4 aut | |
700 | 0 | |a Kaori Kubota |e verfasserin |4 aut | |
700 | 0 | |a Takehiro Kawashiri |e verfasserin |4 aut | |
700 | 0 | |a Chise Taniguchi |e verfasserin |4 aut | |
700 | 0 | |a Shutaro Katsurabayashi |e verfasserin |4 aut | |
700 | 0 | |a Katsunori Iwasaki |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Journal of Pharmacological Sciences |d Elsevier, 2017 |g 147(2021), 1, Seite 114-117 |w (DE-627)1760631620 |x 13478613 |7 nnns |
773 | 1 | 8 | |g volume:147 |g year:2021 |g number:1 |g pages:114-117 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.jphs.2021.06.004 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/0a7262820c5a46f095577221d18b3940 |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1347861321000608 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1347-8613 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 147 |j 2021 |e 1 |h 114-117 |
author_variant |
n e ne y g yg r t rt h i hi s y sy t w tw k k kk t k tk c t ct s k sk k i ki |
---|---|
matchkey_str |
article:13478613:2021----::bdlssprseoailtnnuemcaiaaldnann |
hierarchy_sort_str |
2021 |
callnumber-subject-code |
RM |
publishDate |
2021 |
allfields |
10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117 |
spelling |
10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117 |
allfields_unstemmed |
10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117 |
allfieldsGer |
10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117 |
allfieldsSound |
10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117 |
language |
English |
source |
In Journal of Pharmacological Sciences 147(2021), 1, Seite 114-117 volume:147 year:2021 number:1 pages:114-117 |
sourceStr |
In Journal of Pharmacological Sciences 147(2021), 1, Seite 114-117 volume:147 year:2021 number:1 pages:114-117 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology |
isfreeaccess_bool |
true |
container_title |
Journal of Pharmacological Sciences |
authorswithroles_txt_mv |
Nobuaki Egashira @@aut@@ Yu Goto @@aut@@ Ryota Takahashi @@aut@@ Hikari Iba @@aut@@ Shota Yamamoto @@aut@@ Takuya Watanabe @@aut@@ Kaori Kubota @@aut@@ Takehiro Kawashiri @@aut@@ Chise Taniguchi @@aut@@ Shutaro Katsurabayashi @@aut@@ Katsunori Iwasaki @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
1760631620 |
id |
DOAJ006181082 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006181082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2021.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006181082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a7262820c5a46f095577221d18b3940</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ibudilast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxaliplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu Goto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryota Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hikari Iba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shota Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaori Kubota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chise Taniguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Katsurabayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsunori Iwasaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">147(2021), 1, Seite 114-117</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:147</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:114-117</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2021.06.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a7262820c5a46f095577221d18b3940</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861321000608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">147</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">114-117</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Nobuaki Egashira |
spellingShingle |
Nobuaki Egashira misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
authorStr |
Nobuaki Egashira |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760631620 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
13478613 |
topic_title |
RM1-950 Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats Ibudilast Oxaliplatin Peripheral neuropathy |
topic |
misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology |
topic_unstemmed |
misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology |
topic_browse |
misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of Pharmacological Sciences |
hierarchy_parent_id |
1760631620 |
hierarchy_top_title |
Journal of Pharmacological Sciences |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1760631620 |
title |
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
ctrlnum |
(DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 |
title_full |
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
author_sort |
Nobuaki Egashira |
journal |
Journal of Pharmacological Sciences |
journalStr |
Journal of Pharmacological Sciences |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
container_start_page |
114 |
author_browse |
Nobuaki Egashira Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki |
container_volume |
147 |
class |
RM1-950 |
format_se |
Elektronische Aufsätze |
author-letter |
Nobuaki Egashira |
doi_str_mv |
10.1016/j.jphs.2021.06.004 |
author2-role |
verfasserin |
title_sort |
ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
callnumber |
RM1-950 |
title_auth |
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
abstract |
Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. |
abstractGer |
Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. |
abstract_unstemmed |
Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
container_issue |
1 |
title_short |
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats |
url |
https://doi.org/10.1016/j.jphs.2021.06.004 https://doaj.org/article/0a7262820c5a46f095577221d18b3940 http://www.sciencedirect.com/science/article/pii/S1347861321000608 https://doaj.org/toc/1347-8613 |
remote_bool |
true |
author2 |
Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki |
author2Str |
Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki |
ppnlink |
1760631620 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.jphs.2021.06.004 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T19:26:58.772Z |
_version_ |
1803587230131814400 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006181082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2021.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006181082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a7262820c5a46f095577221d18b3940</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ibudilast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxaliplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu Goto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryota Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hikari Iba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shota Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaori Kubota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chise Taniguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Katsurabayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsunori Iwasaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">147(2021), 1, Seite 114-117</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:147</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:114-117</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2021.06.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a7262820c5a46f095577221d18b3940</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861321000608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">147</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">114-117</subfield></datafield></record></collection>
|
score |
7.4005775 |